Screener
Eligibility screening
Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neo…
18 US sites in AZ, CT, DE, FL +9
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.